Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GAPDH | P04406 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19644387 | 0.88 | PTPN7 (0.40) | F12MEN1KMT2AMAPTPTPN7 | |
| SCHEMBL19127839 | 0.81 | F12 (0.50) | F12F2 | |
| SCHEMBL19643629 | 0.81 | F12 (0.46) | F12MEN1KMT2AMAPTKDM4E | |
| SCHEMBL22492635 | 0.81 | F12 (0.48) | F12F2 | |
| SCHEMBL22492379 | 0.81 | F12 (0.48) | F12MEN1KMT2AMAPTPTPN7 | |
| SCHEMBL22492372 | 0.81 | F12 (0.48) | F12MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL22492483 | 0.79 | NPC1 (0.50) | F12MEN1KMT2AMAPTKDM4E | |
| SCHEMBL22492436 | 0.79 | F12 (0.49) | F12KMT2APTPN7KDM4EHSD17B10 | |
| SCHEMBL22492485 | 0.78 | F12 (0.47) | F12MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL20804979 | 0.77 | UGT2B17 (0.39) | F12MEN1KMT2AMAPTPTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | THE ROCKEFELLER UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | THE ROCKEFELLER UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| EP-3716972-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | The Rockefeller University (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111670034-A | Pyranopyrazoles and pyrazolopyridines immunomodulators for the treatment of autoimmune diseases | 洛克菲勒大学 | 2020-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI, TFPI2, SERPINC1 | F12 14/4885MEN1 2278/4885KMT2A 4536/4885 |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | TFPI, TFPI2, SERPINC1 | F12 14/4885MEN1 2278/4885KMT2A 4536/4885 |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI, TFPI2, SERPINC1 | F12 14/4885MEN1 2278/4885KMT2A 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.